Abiopharma

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

DarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

New Form 6-K - Valneva SE Filed: 2025-09-03 AccNo: 0001836564-25-000014 Size: 46 KB

Silo Pharma Notification (SILO)

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio